Loading cancer entity…
Loading cancer entity…
Clinical trials
673 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (86)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07767630 | Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04947501 | A Study of N9 Chemotherapy in Children With Neuroblastoma | active not recruiting | Early Phase 1 | 26 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT06942039 | Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation | recruiting | Early Phase 1 | 15 | C17 CouncilOTHER | 1 | Jul 14, 2026 | clinicaltrials |
| NCT03189706 | Study of Chemoimmunotherapy for High-Risk Neuroblastoma | active not recruiting | Early Phase 1 | 48 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jul 6, 2026 | clinicaltrials |
| NCT03541720 | 18F-Fluorodopamine PET Studies of Neuroblastoma and Pheochromocytoma | active not recruiting | Early Phase 1 | 13 | St. Jude Children's Research HospitalOTHER | 1 | Jun 17, 2026 | clinicaltrials |
| NCT04040088 | An Investigational Scan (68Ga-DOTATATE PET/CT) in Diagnosing Pediatric Metastatic Neuroendocrine Tumors | active not recruiting | Early Phase 1 | 20 | Mayo ClinicOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT02245997 | Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma | completed | Early Phase 1 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT07067346 | Safety & Efficacy of IR-101 in Relapsed/Refractory Neuroblastoma | recruiting | Early Phase 1 | 10 | Sichuan UniversityOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07090538 | GSL Synthetase Inhibitor Plus GM-CSF and/ or Immune Checkpoint Inhibitor in Previously Treated High-Risk Neuroblastoma. | not yet recruiting | Early Phase 1 | 10 | Chinese PLA General HospitalOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT06684639 | A Study on the Efficacy of GD2-CAR T Cells in the Treatment of Neuroblastoma | recruiting | Early Phase 1 | 30 | The General Hospital of Western Theater CommandOTHER | 1 | Dec 20, 2024 | clinicaltrials |
| NCT05069220 | 18F-MFBG PET/CT in the Evaluation of Neural Crest Tumor | recruiting | Early Phase 1 | 150 | Peking Union Medical College HospitalOTHER | 1 | Mar 1, 2024 | clinicaltrials |
| NCT04049864 | DNA Vaccination Against Neuroblastoma | unknown | Early Phase 1 | 12 | Belarusian Research Center for Pediatric Oncology, Hematology and ImmunologyOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT01583842 | 124I-Metaiodobenzylguanidine (MIBG) PET/CT Diagnostic Imaging and Dosimetry for Patients With Neuroblastoma: A Pilot Study | terminated | Early Phase 1 | 10 | Miguel PampaloniOTHER | 1 | May 14, 2021 | clinicaltrials |
| NCT04864821 | Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor | unknown | Early Phase 1 | 24 | PersonGen BioTherapeutics (Suzhou) Co., Ltd.INDUSTRY | 0 | May 6, 2021 | clinicaltrials |
| NCT00790413 | Haploidentical Stem Cell Transplantation in Neuroblastoma | unknown | Early Phase 1 | 15 | Lund University HospitalOTHER | 1 | Feb 21, 2021 | clinicaltrials |
Data updated 22 days agoSource updated Aug 21, 2026source: clinicaltrials